Insider Buying: enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases $24,338.60 in Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Matthew Jenusaitis purchased 9,620 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was bought at an average cost of $2.53 per share, for a total transaction of $24,338.60. Following the purchase, the director now directly owns 16,545 shares in the company, valued at $41,858.85. This trade represents a 138.92 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

enVVeno Medical Stock Down 3.1 %

NVNO opened at $2.82 on Thursday. The firm’s fifty day simple moving average is $3.20 and its two-hundred day simple moving average is $4.32. enVVeno Medical Corporation has a 52-week low of $2.45 and a 52-week high of $6.97. The company has a market cap of $49.45 million, a price-to-earnings ratio of -2.19 and a beta of 1.22.

enVVeno Medical (NASDAQ:NVNO) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). On average, research analysts forecast that enVVeno Medical Corporation will post -1.3 EPS for the current year.

Institutional Trading of enVVeno Medical

Several large investors have recently made changes to their positions in NVNO. Westside Investment Management Inc. lifted its holdings in enVVeno Medical by 128.0% in the 3rd quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock valued at $297,000 after purchasing an additional 49,613 shares in the last quarter. Hohimer Wealth Management LLC acquired a new stake in shares of enVVeno Medical in the third quarter valued at about $286,000. Geode Capital Management LLC lifted its stake in shares of enVVeno Medical by 7.8% in the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after buying an additional 10,902 shares in the last quarter. Maven Securities LTD acquired a new position in enVVeno Medical during the third quarter worth about $295,000. Finally, Corsair Capital Management L.P. purchased a new stake in enVVeno Medical during the 3rd quarter valued at about $390,000. 34.71% of the stock is currently owned by hedge funds and other institutional investors.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).